Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PHGDH | O43175 | 15/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.35 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | CCR1 | P32246 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20768453 | 0.91 | PHGDH (0.48) | PHGDH | |
| SCHEMBL26373066 | 0.91 | PHGDH (0.43) | PHGDH | |
| SCHEMBL19343456 | 0.90 | PHGDH (0.43) | PHGDHALDH1A1TDP1LGALS8LGALS3 | |
| SCHEMBL20793599 | 0.89 | PHGDH (0.46) | PHGDHALDH1A1TDP1LGALS8LGALS3 | |
| SCHEMBL19343471 | 0.89 | PHGDH (0.48) | PHGDH | |
| SCHEMBL20793598 | 0.87 | PHGDH (0.41) | PHGDHALDH1A1TDP1LGALS8LGALS3 | |
| SCHEMBL19344123 | 0.86 | ALDH1A1 (0.38) | ALDH1A1TDP1LGALS8LGALS3CCR1 | |
| SCHEMBL19343481 | 0.83 | PHGDH (0.48) | PHGDHALDH1A1TDP1LGALS8LGALS3 | |
| SCHEMBL19331352 | 0.82 | PHGDH (0.46) | PHGDHRXFP1CCR1 | |
| SCHEMBL19344079 | 0.81 | PHGDH (0.46) | PHGDHALDH1A1RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312536-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS, INC. | 2023-10-05 | — | — | US | disclosed |
| US-11634412-B2 | 3-phosphoglycerate dehydrogenase inhibitors and uses thereof | RAZE THERAPEUTICS, INC. (US) | 2023-04-25 | — | — | US | disclosed |
| US-20230009122-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS, INC. | 2023-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11634412-B2 | 3-phosphoglycerate dehydrogenase inhibitors and uses thereof | PHGDH, G6PD, PGD | PHGDH 1/4885ALDH1A1 222/4885TDP1 832/4885 |
| US-20230009122-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | PHGDH, G6PD, PGD | PHGDH 1/4885ALDH1A1 222/4885TDP1 832/4885 |
| US-20230312536-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | PHGDH, G6PD, PGD | PHGDH 1/4885ALDH1A1 222/4885TDP1 832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.